Bruker (NASDAQ:BRKR) Upgraded at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Bruker (NASDAQ:BRKR) from a strong sell rating to a strong-buy rating in a report released on Monday,Zacks reports.

Other analysts also recently issued reports about the stock. TD Cowen reissued a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Stifel Nicolaus set a $50.00 price objective on Bruker in a research note on Wednesday, August 5th. Citigroup decreased their price objective on Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research note on Monday, August 31st. Finally, UBS Group began coverage on Bruker in a research report on Wednesday, September 9th. They set a “neutral” rating and a $65.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.00.

Bruker Stock Down 2.5%

Shares of BRKR opened at $59.67 on Monday. Bruker has a 1 year low of $30.09 and a 1 year high of $65.30. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The stock has a 50 day simple moving average of $58.27 and a two-hundred day simple moving average of $50.44. The firm has a market cap of $9.09 billion, a P/E ratio of -85.24, a P/E/G ratio of 1.87 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The firm had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. During the same period in the previous year, the business posted $0.32 EPS. The business’s quarterly revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts forecast that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 21st. Bruker’s dividend payout ratio (DPR) is -28.57%.

Insider Activity

In other Bruker news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president owned 134,806 shares in the company, valued at approximately $7,127,193.22. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 27.20% of the company’s stock.

Institutional Trading of Bruker

A number of institutional investors have recently modified their holdings of the company. Pallas Capital Advisors LLC purchased a new position in Bruker during the 2nd quarter valued at about $570,746,000. Sculptor Capital LP grew its position in shares of Bruker by 9.0% in the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock worth $118,112,000 after buying an additional 270,000 shares during the last quarter. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Bruker in the 2nd quarter worth approximately $169,899,000. Dimensional Fund Advisors LP increased its stake in shares of Bruker by 23.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company’s stock valued at $84,556,000 after buying an additional 448,440 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Bruker by 317.7% during the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after buying an additional 1,756,460 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.